JR Rahn

The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to suggest 50 million jobs may be vulnerable to permanent layoffs, a scenario that may fuel the emergence of a mental health catastrophe. In a bid to address the arrival of a national health crisis, Mind...

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. Exploring High-Dose LSD...

The Canadian NEO Exchange announced Tuesday that neuro-pharmaceutical company Mind Medicine Inc. (OTC:MMEDF) (NEO: MMED) will make its public market debut under the symbol "MMED." The exchange's approval of MindMed makes it the first psychedelic company to be publicly listed,...

Earlier this year, Canopy Growth (NYSE: CGC) co-founder and former CEO Bruce Linton invested in a neuropharmaceutical company, Mind Medicine Inc. MindMed is a psychedelic research company that’s developing non-hallucinogenic medicine from psychedelic sources. The company has also...